Additional file 1 of Feasibility of a physical activity intervention for children and adolescents with anxiety and depression

Additional file 1. Contentment questionnaire

Data_Sheet_1_Case report: ADHD and prognosis in tyrosinemia type 1.docx

Neurometabolic disorders such as tyrosinemia type 1 (TYRSN1) may interfere with brain metabolism and show symptoms of attention-deficit hyperactivity disorder (ADHD) in patients treated with the enzyme inhibitor nitisinone [2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione, NTBC]. It has been reported that ADHD treatment improves treatment compliance, which is imperative for the long-term prognosis of patients with TYRSN1. In this study, we report the case of a male patient who was diagnosed with TYRSN1 at 3 months of age and was subsequently treated with NTBC, restricted protein intake, and amino acids supplementation. At 7 years of age, he was referred for neuropsychiatric assessment, diagnosed with ADHD, and treated with methylphenidate. The effects of the treatment were monitored via parental interviews, questionnaires covering ADHD symptoms, and a continuous performance test. A reduction in ADHD symptoms, particularly inattentiveness, was observed across all measures. The early identification of ADHD and the treatment of neurometabolic disorders, such as TYRSN1, may be important from a lifetime perspective as this may improve the prognosis of the medical condition as well.</p

Neuro-psychological testing results from KABAC II (General cognition, MPI and Working memory), T.O.V.A (attention and inhibition) and CCT (cognitive flexibility).

<p>Country-pooled results showing linear regression unadjusted and adjusted models with EBF status at 12 weeks as the dependent variable, 1-week recall.</p

Average school test results and height for age z-scores (HAZ) by intervention and control arms.

<p>Average school test results and height for age z-scores (HAZ) by intervention and control arms.</p

Emotional-behavioural symptom results from the Strengths and Difficulties questionnaire, parent version.

<p>Country-pooled results showing linear regression unadjusted and adjusted models with trial arm as the dependent variable, N = 1048.</p

Baseline characteristics, categorical variables given.

<p>Baseline characteristics, categorical variables given.</p

Emotional-behavioural symptom results from the Strengths and Difficulties questionnaire, parent version.

<p>HAZ: Height for age z-score. Country-pooled results showing linear regression unadjusted and adjusted models with EBF status at 12 weeks as the dependent variable, 1-week recall.</p

Neuro-psychological testing results from KABAC II (General cognition, MPI and Working memory), T.O.V.A (attention and inhibition) and CCT (cognitive flexibility).

<p>Country-pooled results showing linear regression unadjusted and adjusted models with trial arm as the dependent variable.</p